|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.160 USD | -4.41% |
|
+11.18% | +33.83% |
| Dec. 30 | ASX Midday Sector Update: Energy Stocks Climb, Real Estate Struggles | MT |
| Dec. 30 | Renergen Securities Suspended From Quotation | MT |
| Capitalization | 936M 806M 751M 699M 1.3B 84.55B 1.39B 8.63B 3.4B 40.42B 3.51B 3.44B 148B | P/E ratio 2025 * |
-5.98x | P/E ratio 2026 * | -13.9x |
|---|---|---|---|---|---|
| Enterprise value | 936M 806M 751M 699M 1.3B 84.55B 1.39B 8.63B 3.4B 40.42B 3.51B 3.44B 148B | EV / Sales 2025 * |
102x | EV / Sales 2026 * | 23.7x |
| Free-Float |
65.52% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | -4.41% | ||
| 1 week | +11.18% | ||
| Current month | +33.83% | ||
| 1 month | +25.83% | ||
| 3 months | -43.26% | ||
| 6 months | -9.25% | ||
| Current year | +33.83% |
| 1 week | 6.91 | 7.75 | |
| 1 month | 5.24 | 8.08 | |
| Current year | 5.35 | 8.08 | |
| 1 year | 3.65 | 14.49 | |
| 3 years | 0.28 | 14.49 | |
| 5 years | 0.28 | 14.49 | |
| 10 years | 0.28 | 14.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Ainscow
CEO | Chief Executive Officer | 50 | 2025-09-30 |
| Director of Finance/CFO | 61 | 2024-06-30 | |
| Chief Operating Officer | 47 | 2026-01-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Mann
CHM | Chairman | 50 | 2021-09-12 |
Duncan Moore
BRD | Director/Board Member | 67 | 2021-09-30 |
Todd Wider
BRD | Director/Board Member | 61 | 2021-09-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.41% | +11.18% | +37.43% | +336.59% | 936M | ||
| -3.76% | -4.81% | +38.33% | +185.65% | 925B | ||
| +0.47% | +6.72% | +51.46% | +26.60% | 529B | ||
| -2.32% | -3.29% | +26.50% | +41.11% | 383B | ||
| +0.46% | +1.86% | +30.01% | +18.51% | 368B | ||
| -2.23% | -1.06% | +31.72% | +20.33% | 291B | ||
| -1.36% | +0.63% | +26.39% | +35.48% | 274B | ||
| -0.04% | -0.02% | +10.87% | -1.14% | 275B | ||
| -3.45% | -1.39% | -39.64% | -22.02% | 252B | ||
| +0.32% | -0.02% | +22.72% | +21.46% | 178B | ||
| Average | -1.63% | +1.21% | +23.58% | +66.26% | 347.57B | |
| Weighted average by Cap. | -1.67% | -0.56% | +28.02% | +63.94% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 9.2M 7.92M 7.38M 6.87M 12.78M 831M 13.71M 84.83M 33.38M 397M 34.49M 33.78M 1.46B | 39.44M 33.97M 31.66M 29.45M 54.79M 3.56B 58.78M 364M 143M 1.7B 148M 145M 6.25B |
| Net income | -107M -92.37M -86.08M -80.08M -149M -9.69B -160M -989M -389M -4.63B -402M -394M -16.99B | -27.65M -23.82M -22.2M -20.65M -38.42M -2.5B -41.21M -255M -100M -1.19B -104M -102M -4.38B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
136
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-15 | 7.480 $ | +5.50% | 8,570,272 |
| 26-01-14 | 7.090 $ | -0.98% | 5,758,285 |
| 26-01-13 | 7.160 $ | -4.41% | 5,102,105 |
| 26-01-12 | 7.490 $ | -0.27% | 5,429,100 |
| 26-01-09 | 7.510 $ | +16.61% | 19,154,904 |
End-of-day quote Nasdaq, January 12, 2026
More quotesSell
Buy

Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.480USD
Average target price
13.00USD
Spread / Average Target
+73.80%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ASPI Stock
Select your edition
All financial news and data tailored to specific country editions
















